Glucokinase Activator Salt Forms for Solubility and Stability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing glucokinase activators for treating diabetes mellitus face challenges such as hypoglycemia, increased triglycerides, and loss of efficacy over time, and there is a need for drug forms with improved solubility, stability, and suitability for large-scale manufacturing.
Innovation Solution
Development of novel salt and co-crystal forms of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid, including sodium, piperazine, and hydrochloride salts, characterized by specific XRPD, TGA, and DSC profiles, to enhance GK activation and stability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing glucokinase activators are used to treat diabetes mellitus, then glycemic control is achieved, but hypoglycemia and increased triglycerides occur
Solution Approach 1:
The patent applies local quality by developing liver-selective glucokinase activators that concentrate their action in the liver tissue. This is achieved through specific molecular structure design (Compound 1 and its salts/co-crystals) that enables selective accumulation in hepatocytes, thereby achieving glycemic control through hepatic glucose production suppression without causing systemic hypoglycemia or triglyceride elevation.
Solution Approach 2:
The patent employs parameter changes by creating multiple salt and co-crystal forms of the active compound (sodium salt, piperazine salt, hydrochloride salt, and various co-crystals). These different polymorphic forms exhibit varying solubility, dissolution rate, and stability parameters, allowing optimization of the therapeutic profile to achieve effective glycemic control while minimizing adverse effects through selective dosing and formulation.
2Reliability
If multiple small-molecule glucokinase activators are developed, then therapeutic promise is improved, but loss of efficacy over time occurs
Solution Approach 1:
The patent applies preliminary action through the development of optimized salt and co-crystal formulations that provide sustained release and stable plasma concentrations. The specific crystalline forms (Forms I-X) are designed to maintain consistent drug availability over time, preventing the tolerance development and efficacy loss observed with earlier activators. This is achieved through controlled dissolution kinetics and enhanced metabolic stability.
Solution Approach 2:
The patent utilizes composite materials by creating co-crystal formulations that combine the active glucokinase activator with co-formers having complementary properties. These composite crystalline structures (e.g., co-crystals with oxalic acid, tartaric acid, or piperazine) provide synergistic effects that enhance both the duration and consistency of glucokinase activation, thereby maintaining therapeutic efficacy over extended periods.
3Reliability
If Compound 1 is formulated as free acid, then GK activation is achieved, but solubility and stability for manufacturing are limited
Solution Approach 1:
The patent applies parameter changes by transforming the free acid form of Compound 1 into various salt and co-crystal forms. This fundamental parameter change in the chemical state (from neutral acid to ionic salt or molecular complex) dramatically improves solubility in aqueous media, enhances chemical stability during storage and processing, and facilitates large-scale manufacturing while preserving the essential glucokinase activation activity.
Solution Approach 2:
The patent uses intermediaries (counter-ions such as sodium, piperazine, hydrochloride, and co-forming molecules) that mediate between the active compound and the formulation environment. These intermediary substances enable the active compound to achieve optimal solubility and stability characteristics for manufacturing and administration without altering the core pharmacophore responsible for glucokinase activation.
4Ease of manufacture
If different salt or co-crystal forms are developed, then solubility and stability are improved, but formulation complexity increases
Solution Approach 1:
The patent applies segmentation by systematically categorizing and characterizing each salt and co-crystal form (Forms I-X) with distinct identification criteria (XRPD patterns, DSC profiles, solubility data). This segmented approach allows each formulation variant to be independently optimized and manufactured using standardized protocols, thereby managing complexity through systematic organization rather than creating monolithic complex formulations.
Data Source
AI summary
Sodium, piperazine, and hydrochloride salts or co-crystals of {2-[3-cyclohexyl-3-(trans-4-propoxy-cyclohexyl)-ureido]-thiazol-5-ylsulfanyl}-acetic acid (“Compound 1”) are provided herein.